Few pursuits are more urgent than boosting cancer survival rates, and a rising number of European early-stage startups are leveraging new methods to do just that.
As complex as it is to combat the disease, cancer tech players are now equipped with more powerful data-driven weapons to advance their missions. The spread of new applications we’re seeing is wide and includes digital patients’ pathway solutions, AI-powered drug design and discovery, clinical trials support and predictive biomarkers for cancer therapy.
Importantly, startups are creating efficient solutions outside of traditional biotech approaches. In-silico modelling, which uses computer simulations to model biological processes as opposed to lab-based techniques, is a prime example of the new approach to outrunning cancer. And the results are showing promise.
Sifted scouted hundreds of early-stage oncology startups to map out the cream of the crop, scanning all rounds up to seed stage and young unfunded companies with a cancer focus. Startups with relevant tech stacks but limited oncology focus were excluded. We then scored companies on a weighted methodology accounting for momentum, team strength, growth signals and product differentiation. Below is the result.
A message from our sponsor Debiopharm Innovation Fund
Are you a startup with innovative ideas that can revolutionise cancer care and pharmaceutical R&D?
Debiopharm is launching a new seed funding activity. Pitch your disruptive innovation to Debiopharm Innovation Fund for a potential investment. For more information about its mission and how you can contribute, visit the website.